A monoclonal antibody drug reduced the risk of smoldering myeloma progressing to multiple myeloma in patients at high risk for disease progression.

by Sandra Gordon

New research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.

by Laura Gesualdi-Gilmore

Adding a CDK 4/6 inhibitor extends progression-free survival for people with metastatic HR-positive, HER2-positive breast cancer.

by Thomas Celona

Forward Look

Hematologist-oncologist C. Ola Landgren explains how measuring minimal residual disease could be useful in multiple myeloma clinical trials.

by Anna Azvolinsky

From the Editor-in-Chief

A recently approved therapy targets abnormal enzymes produced by gene defects.

by William G. Nelson, MD, PhD

Forward Look

More patients are receiving CAR T-cell therapy for large B-cell lymphoma.

by Leah Lawrence

Forward Look

A new approach that uses a probe to freeze tumor cells followed by an infusion of immune-boosting drugs shows promising results in an early clinical trial.

Forward Look

Targeted therapy extends progression-free survival in people with stage III EGFR-mutated lung cancer.

by Darcy Lewis

With targeted therapy options available for a growing number of cancer types, biomarker testing is making a difference for more people with solid cancers.

by Kendall K. Morgan

Survivor Profile

Margie Wilson is helping Black women understand their risk for endometrial cancer and teaching them not to ignore the warning signs.

by Taayoo Murray